Citigroup Inc Biogen Inc. Call Options Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$189.07 - $236.8 $2.84 Million - $3.55 Million	-15,000 Reduced 82.42%	3,200 $620,000
Q2 2024 Aug 12, 2024	BUY	$190.52 - $236.72 $2.86 Million - $3.55 Million	15,000 Added 468.75%	18,200 $4.22 Million
Q1 2024 May 10, 2024	SELL	$212.02 - $267.71 $9.52 Million - $12 Million	-44,900 Reduced 93.35%	3,200 $690,000
Q4 2023 Feb 09, 2024	SELL	$222.59 - $267.94 $7.15 Million - $8.6 Million	-32,100 Reduced 40.02%	48,100 $12.4 Million
Q3 2023 Nov 09, 2023	BUY	$253.3 - $285.89 $10.1 Million - $11.4 Million	40,000 Added 99.5%	80,200 $20.6 Million
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $6.83 Million - $7.89 Million	-24,800 Reduced 38.15%	40,200 $11.5 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $16.7 Million - $19 Million	65,000 New	65,000 $18.1 Million
Q3 2022 Nov 10, 2022	BUY	$194.69 - $268.46 $2.92 Million - $4.03 Million	15,000 Added 60.0%	40,000 $10.7 Million
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $6.75 Million - $8.03 Million	-36,000 Reduced 59.02%	25,000 $5.1 Million
Q3 2021 Nov 10, 2021	BUY	$282.99 - $369.05 $17.3 Million - $22.5 Million	61,000 New	61,000 $17.3 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.